News & Updates

Treatment with a single-pill low-dose combination (LDC) of amlodipine, losartan, and chlorthalidone (ALC) results in similar reductions in blood pressure (BP) to those with standard-dose amlodipine monotherapy and greater BP decrease than losartan monotherapy over 8 weeks among patients with mild-to-moderate hypertension, reveals a study.

A systematic review and meta-analysis suggest that the MANTA^® vascular closure device (MVCD) is a promising, effective, and reliable approach for achieving haemostasis after percutaneous veno-arterial extracorporeal membrane oxygenation (VA-ECMO) decannulation.

Exposure to severe maternal morbidity appears to put babies at risk of cerebral palsy, according to a study.

A 1-day course of antibiotics is noninferior to the standard 4–7-day regimen for achieving clinical cure in patients with acute cholangitis who have undergone adequate biliary drainage, according to the COBRA trial presented at ESCMID Global 2026.

Impulse dyscontrol is the leading mild behavioural impairment (MBI) domain among older adults of Chinese ethnicity across multiple regions cohorts including Singapore, according to a study.

Many routine baseline screening and monitoring tests show no clear benefit to psoriasis patients prescribed biologic treatments, according to a study.

Treatment with aluminium adjuvanted vaccines does not appear to induce serious or long-term health outcomes, suggest the results of a systematic review. Local hypersensitivity reactions, such as persistent nodules and granulomas, are the most consistently recorded reactions.

In the ATOM*3 trial, atropine 0.01% did not prevent the onset of myopia in young children with premyopia (SE** +1.00 to −0.49 dioptres [D]) and low myopia (SE −0.50 to −1.50 D), but there was a trend towards less progression with atropine.

In patients with perianal Crohn’s disease (pCD) treated in routine clinical practice, the use of upadacitinib appears to have a beneficial effect on fistula outcomes, with a more pronounced effect seen for anti-TNF–naïve patients and those with shorter disease duration, according to a multicentre retrospective cohort study.